Harliku becomes the first FDA-approved treatment for alkaptonuria, indicated to reduce homogentisic acid levels in affected ...

Approval of first twice-yearly HIV pre-exposure prophylaxis was based on results from the Phase III PURPOSE 1 and PURPOSE 2 ...

The investigational MRI contrast agent, gadoquatrane, is designed to deliver effective imaging at a significantly reduced gadolinium dose, supporting safer repeat use in adults and pediatric patients.

Pharmaceutical innovation has had a huge impact on society by extending and improving the quality of life, but this extends to a larger healthy working population and improvements in gross domestic ...

Pharmaceutical Executive delivers strategic insights for pharma leaders, covering commercialization, market access, R&D, and leadership to drive success.

For more than three decades, U.S. pharmacy policy has operated under a consistent—if complex—structure: Well-intended ...

Under the new initiative, companies may receive a voucher enabling FDA review to be shortened from the standard 10–12 months to just 1–2 months following final application submission if the drug ...

Jim Weiss, founder and chairman of Real Chemistry, and the 2025 HBA Honorable Mentor, discusses the foundation and journey ...

Johnson & Johnson submitted a supplemental Biologics License Application to expand Stelara’s use to children aged two years ...

Results from the Phase III TEMPLE trial show that patients administered Qulipta (atogepant) experienced significantly fewer ...

The key to improving SFE in 2025 lies in fundamentally reorienting measurement from representative activities to the value ...

Insights on ways pharmacy benefit managers can tap earned media to enhance their reputation—and demonstrate value through ...